Philadelphia (Ph')-positive acute lymphoblastic leukemia (ALL) is highly associated with two forms of chimeric bcrab1 proteins: P1 90bcr-ab' and P210bc'-'b'. Whereas P21 also occurs in chronic myeloid leukemia, P1 90bcr-ab' is uniquely expressed in Ph'-positive ALL. As a consequence, p i gobcr-ab1 is preeminently a tumor-specific marker in leukemic cells of ALL patients. Because P1 is composed of the normal bcr and ab1 proteins, the major part of the p i gobcr-ab1 molecule comprises nontumor-specific determinants. The joining region between bcr and abl, newly generated during the Ph' translocation, is exclusively a tumor-specific epitope on the P1 90bc'-ab' molecule. Therefore, only antibodies against the bcr-ab/ joining region will H E PHILADELPHIA (Ph') chromosome, a minute T chromosome 22, is found in 90% of all patients with chronic myeloid leukemia (CML).' Therefore, this chromosome is regarded as the cytogenetic hallmark of CML. However, the Ph' chromosome has also been reported to occur in some patients with other types of leukemia. Thus, in the leukemic cells of 2% to 3% of all patients with acute myeloid leukemia, the Ph' chromosome can be detected.' Moreover, in childhood acute lymphoblastic leukemia (ALL), a 2% to 10% incidence is reported, whereas in adult ALL the Ph' chromosome is found to be the most frequent chromosomal aberration, with an incidence of 20% to 30%.3*4
chimeric bcr-abl gene, encoding a 8.5-kilobase (kb) messenger R N A (mRNA) that is translated into a 210-Kd protein, With respect to the Ph' translocation process, Ph'-positive ALL patients are heterogeneousi4: 50% of adults and 10% of children with Ph'-positive ALL show the same bcr-ab1 rearrangement as found in CML. Accordingly, these patients express P210bc"ab1.i4 In contrast, a P190bc'ab1 protein is demonstrated in the other group of ALL patients, including almost all cases of childhood ALL.'*-" We have previously shown a different bcr-ab1 rearrangement in such patient^.',^ Here, breakpoints were noticed in the fist intron of the bcr gene, termed m-bcr-1. The first bcr exon (el) is then spliced to exon 2 of the abl gene (termed a2), resulting in a 7.0-kb bcr-abl mRNA. Therefore, in the chimeric PI 90k'-ab' protein the el-a2 bcr-abl junction is present.
Because P210bcr-ab' as well as P190kr-ab' are expressed exclusively in malignant cells in CML and ALL, these proteins are by definition tumor-specific. However, P2 10bcr-ab' and P190bcr-ab1 are composed of parts of bcr and ab2 molecules, which are, as such, normal cellular proteins. The only tumor-specific determinant on the chimeric proteins is formed just in the joining region between bcr and abl. Recently we have shown that the bcr-abl junction in P2lOk'"I is antigenically exposed on this protein. " In this study we investigate the expression of the el-a2 bcr-abl junction in P190bcr-ab1 in cell lines and in leukemic cells of a Ph'-positive ALL patient. Our data also indicate that the bcr-abl junction in P190bcr-ab' can be recognized by antibodies. These experiments indicate that the tumorspecific joining regions in the bcr-abl fusion proteins are new immunologic markers for CML and ALL diagnosis. 
MATERIALS AND METHODS

Cell Lines
TOM-1 is a cell line derived from a Ph'-positive ALL patient.I9 The cell line was kindly provided by Dr M. Okabe (Sapparo, Japan). K562 and BV173 are cell lines derived from patients during blast crisis of CML.20,2' Cells were cultured in RPMI medium supplemented with 10% fetal calf serum, 100 fig/mL penicillin, and 60 fig/mL streptomycin.
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Patients
Patient L. is a 52-year-old and patient K. is a 44-year-old male ALL patient. Both patients exhibited a standard Philadelphia translocation, t(9,22)(q34;qlI). In both patients the diagnosis precursor B-ALL was based on immunologic and hematologic criteria obtained at presentation. Blast cells were isolated from peripheral blood by Ficoll-Hypaque centrifugation. After cryopreservation using a controlled freezing apparatus (Planer Biomed, Sunbury-onThames, UK). the cells were stored under liquid nitrogen.
Peptide Synthesis, Purifcation. and Conjugation
Peptides were synthesized using solid-phase synthesis as described previ~usly.'~ Purification of the peptides was performed by gel filtration and reverse phase high performance liquid chromatography. A cysteine residue was added to the amino terminus during synthesis. Peptides were crosslinked through free sulfhydryl groups to the carrier protein chicken y globulin (CGG) using mmaleimidobenzoyl-sulfosuccinimide-ester (MBS) ."
Immunizations, Antisera, and Purifcation of Immunoglobulins (Igs)
Flemish rabbits (MBL-TNO, Rijswijk, The Netherlands) were primed intracutaneously with 250 pg protein complex consisting of peptide el-a2 coupled via MBS to CGG, emulsified in an equal volume of complete freund adjuvans (CFA). Rabbits were boosted twice after intervals of 4 weeks; the first time with 250 pg of protein in CFA, the second time with the same dose in incomplete freund adjuvans. Fourteen days after the last boost, rabbits were bled and sera were collected.
Anti-bcr untiserum. Anti-bcr antiserum is a polyclonal rabbit antiserum directed against the amino terminal part of the bcr protein. This antiserum was prepared as described previously.'* The Ig fraction of both antisera was purified by precipitation with 16% Na,SO, (final concentration). The precipitates were dissolved in phosphate-buffered saline and desalted using Sephadex G-25M columns (Pharmacia, Uppsala, Sweden).
Immunoprecipitation and Protein Kinase Reaction
Immunoprecipitation and protein kinase reaction were performed as described previo~sly.'~ except that, in the present study, the tyrosine kinase reaction was performed for 10 minutes at 3OoC instead of IO minutes at 37OC.
Antiserum BP-ALL.
Ampli$cation of cDNA by the Polymerase Chain
Reaction (PCR) Method
Total RNA was extracted according to the LiCI followed by cDNA synthesis by reverse transcriptase. The cDNA bcr amplification was performed using the PCR as described previ~usly.~ For the amplification, bcr primers from exon el and b2 and an obf primer from exon a3 were used. In Fig 1 the primers on the respective cDNA molecules are shown. Twenty-four cycles of the PCR were performed using Tuq polymerase. The samples were electrophorized, and transferred to nylon filter (zeta probe). Filters were hybridized to 32P end-labeled oligonucleotides, spanning the el-a2. and b2-a2 b3-a2 junction^.^ After hybridization the blots were washed and exposed to Fuji XR films (Tokyo, Japan).
RESULTS
Peptides Corresponding to the bcr-ab1 Junction in PI 9ppab'
Based on the previously published nucleotide sequence,' a peptide was synthesized corresponding to the bcr-abl junction in P190kr-ab'. The peptide sequence was chosen in such a way that a short peptide, probably one antigenic determinant, with optimal hydrophilicity pattern was selected. This peptide, termed SP el-a2, consists of the following amino acids:
cys -ala-phe-his-gly-asp-ala-g i lu-ala-leu-gln
As a control peptide b3-a2 (SP b3-a2) was constructed corresponding to the b3-a2 joining region in the CMLspecific protein P210kr-ab'. SP b3-a2 has the following amino acid sequence:
cys -1ys-gln-ser-ser-li ys-ala-leu-gln-arg-pro
Amino-terminal cysteine residues were added to both p e p tides to provide a coupling site for carrier molecules. Because fusion of the bcr and abl genes in both P190kr-ab' and P210ber-ab' occurs in a coding triplet, the glu in S P el-a2 and the second lys in SP b3-a2 are newly generated by the translocation Figure 1 schematically shows the respective chimeric bcr-ab1 mRNAs and proteins as occurring in ALL and CML. All fusion proteins share the abl carboxy terminal amino acids, but differ at the amino terminal bcr sequence. As a consequence the synthetic peptides also differ at their amino terminus and have the same ab1 terminal amino acids. First, presence of PI 90kr-ab' mRNA comprising the el-a2 bcr-abl junction in our TOM-I cells had to be confirmed. To this purpose the highly sensitive PCR technique was performed. The bcr-abl cDNA was amplified and hybridized to oligonucleotides specific for the el -a2, b2-a2, and the b3-a2 joining in the chimeric cDNA.
As shown in Fig 2, a 298 -base pair (bp) fragment, specific for the el-a2 joining, was amplified in the TOM-I cells (lane 3, el-a2 probe). As expected, this fragment was not amplified in both CML cell lines K562 and BV173. However, a 394-bp fragment specific for the b3-a2 joining was found to be present after amplification in K562 cells (Fig 2, lane 1, b3-a2 probe), while a 3 19-bp fragment, specific for a b2-a2 joining, was detected in BV173 cells (Fig 2, lane 2, b2-a2 -P210 P190 -
Antibody Binding to bcr-ab1 Chimeric Proteins
Antiserum BP-ALL was raised against SP el-a2. Reactivity of BP-ALL with native bcr-abl chimeric proteins and P210kr--"b' in different cell lines was tested with an immunoprecipitation assay followed by an autophosphorylation reaction. As shown in Fig 2, TOM-I cells contain mRNA comprising the el-a2 bcr-abl junction. However, to confirm that this mRNA was indeed translated into protein, we searched for the presence of P190bcr-ab1 in TOM-I cells. 
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298-a 0 cipitation with the same anti-bcr antiserum (Fig 3, lanes 4  and 6) .
Next, we tested the reactivity of antiserum BP-ALL with
0
. Incubation of BP-ALL with a lysate of TOM-I cells resulted in a clear precipitation of P190k'-ab' (Fig 4, lane  1) . In contrast, BP-ALL did not precipitate P210kr-ab' from either K562 or BV173 (Fig 4, lanes 2 and 3) . These results imply that antiserum BP-ALL specifically recognizes the el-a2 junction domain in P190kr-ab'. We performed peptide blocking studies to confirm this notion. We first incubated BP-ALL with cognate peptide S P el-a2 or, as a control, with a peptide corresponding to the b3-a2 bcr-ab/ junction. Next, TOM-I lysate was added. As shown in Fig 5, serum BP-ALL that are specifically directed against the el-a2 junction.
Precipitation of P190br""b' From Leukemic Cells of a Ph'-Positive ALL Patient
Finally, we investigated whether antiserum BP-ALL precipitated PI 90bcr-ab' from leukemic cells from a Ph'-positive ALL patient. Peripheral blood leukocytes of patient L. were enriched by Ficoll-Hypaque centrifugation. Next, blast cells were lysed and incubated with BP-ALL. The immunoprecipitation was followed by the autophosphorylation assay. Figure 6 shows a clear precipitation of P190"'.ab' from patient L (lane 2). Moreover, analogous to the chimeric proteins in the cell lines, the P210bcr-ab' protein from patient K was not recognized by BP-ALL (Fig 7, lane 3) . This indicates that the el-a2 joining region also in leukemic cells of a Ph'-positive patient antigenically is exposed on the P190bc'-ab' protein.
DISCUSSION
Chromosomal abnormalities in ALL are frequently observed and have prognostic ~ignificance.~~ Particularly, the presence of the Philadelphia chromosome in ALL is of clinical importance. Ph'-positive ALL is associated with a lower remission rate and an overall worse prognosis than Ph'-negative Especially in childhood ALL the Ph' chromosome implicates a bad prognosis.2s It is obvious that for clinical diagnosis antibodies directed against the tumorspecific bcr-abl joining will be useful tools.
Recently we described the development of a polyclonal antiserum directed against the b2-a2 bcr-abl junction in . Now we report on the production of an antiserum, BP-ALL, specifically recognizing the el-a2 bcr-abl joining region in P190bc'-ab'. The specificity of the polyclonal antiserum, raised against a synthetic peptide corresponding to the el-a2 junction, was tested in an immunoprecipitation assay, followed by an autophosphorylation. TOM-1 cells p210kr-abl 18 1 2 were used as a source of Ph'-positive cells. These cells are derived from a Ph'-positive patient by Okabe et al." Since the exact bcr-abl rearrangement in TOM-1 was not described, we performed the highly sensitive PCR technique to verify which bcr-abl junction occurred in TOM-I cells. In these experiments we amplified cDNA from TOM-1 cells comprising the el-a2 bcr-abl junction, indicating a breakpoint in the m-bcr-1. Therefore, presence of P190"r-ab' in these cells could be expected. We confirmed this notion by immunoprecipitation of P1 90"r-ab' from TOM-1 cells using an antiserum directed against the amino-terminus of the bcr gene.
We subsequently showed that antiserum BP-ALL, raised against a peptide corresponding to the el-a2 junction, reacted in a highly specific way with the native protein P190"r-ab' in TOM-1 cells. We argue that P190"r-ab' is precipitated by antibodies in BP-ALL that specifically recognize the el-a2 junction. Antibodies reacting with el and/or a2 sequences only do not play a role, since no other bcr-ab1 chimeric proteins, b2-a2 and b3-a2 P210"r7ab', which also contain el and a2 sequences, were immunoprecipitated by BP-ALL. Moreover, the reaction of BP-ALL with P190h'ab' was specifically inhibited by blocking with cognate peptide. Thus, precipitation of P190"r-"b' was completely abrogated after preincubation of BP-ALL with peptide el-a2. Preincubation with a related peptide SP b3-a2, which eliminates antibodies from BP-ALL directed against a2 sequences, had no effect on the immunoprecipitation of Pl90"'-"'. These observations provide strong evidence that the tumor-specific bcr-abl junction el-a2 is expressed in an antigenic way on the p190bcr-abl molecule. The el -a2 joining region in PI 90"r-ab' in leukemic cells of a Ph'-positive ALL patient is similarly exposed as in the TOM-1 cell line. This observation confirms the idea that the el-a2 epitope can be used as an immunologic marker for Ph'-positive ALL.
The data presented in this report have implications for ALL diagnosis and classification. Here we have demonstrated the antigenic expression of the tumor-specific el -a2 bcr-abl junction in P1 90"r-ab'. In general, antibodies directed against this determinant will be valuable tools in ALL diagnosis and detection of minimal residual disease after clinical treatment, such as chemotherapy and bone marrow transplantation. However, some Ph'-positive ALL patients express P210"r-ab', just as in CML. It has been suggested that these patients are, de facto, CML patients in lymphoid blast crisis without or with a very short chronic phase.' Ph'-positive ALL patients expressing P190"r-ab' would then be de novo ALL patients. Without necessarily subscribing to this hypothesis, it is of interest to investigate whether Ph'-positive ALL with P190"r-ab' differ from the cases of Ph'-positive ALL expressing P210"r-"b' in terms of clinical features like prognosis, response to therapy, and survival. To this purpose a large group of ALL patients has to be studied. The development of well-defined reagents for immunocytochemistry, such as monoclonal antibodies directed against the tumor-specific bcr-abl junction in P190"r'ab' and P210"r-ab', is therefore invaluable for accurate diagnosis of ALL and CML.
